Licensing agreement
Cancer Therapeutics CRC Pty Ltd, of Melbourne, Australia, has announced a collaboration with Duke University, North Carolina, to discover and develop drugs for the treatment of various types of cancer, based on the research of Duke professor Patrick Casey.
Casey and his team at Duke have been investigating lipid signalling pathways and the role of lipid metabolising enzymes in cancer for many years and have developed a series of promising new inhibitors of these enzymes.
Cancer Therapeutics, has taken an exclusive licence to these inhibitors and will start a drug development programme to bring these early-stage compounds towards the clinic. The deal was facilitated by Cancer Therapeutics’s commercial partner, Cancer Research Technology Ltd of the UK and its US subsidiary, Cancer Research Technology Inc.
Cancer Therapeutics was set up in January 2007 by Cancer Research Technology Ltd, the technology transfer arm of the UK charity Cancer Research UK, and some of Australia’s leading academic cancer research institutions.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
